# Viatris

Type: Company (VTRS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/viatris
Canonical HTML page: https://getbiobrief.com/entity/viatris

## Recent coverage (2 stories)

### Invenomic Capital Exits $24M Haemonetics Stake Amid MedTech Underperformance
2026-03-21 01:09:37 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Full story: https://getbiobrief.com/story/invenomic-capital-exits-haemonetics-stake-medtech-underperformance

### Viatris and CRA International Set for Q4 Earnings Amid Pharma Shifts
2026-02-25 05:12:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

Viatris (VTRS) and CRA International (CRAI) are scheduled to report Q4 results on February 26, 2026, providing critical insights into the generic drug market and life sciences consulting demand. These reports come as the industry faces significant regulatory and pricing headwinds from the Inflation Reduction Act and a shifting biosimilar landscape.
Full story: https://getbiobrief.com/story/viatris-crai-q4-earnings-pharma-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.